Physician profile
Brian B Benson
NPI 1730148446
$1,052.23
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $163 · 2021: $396 · 2022: $18.46 · 2023: $23.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $139.00 | 2019-2021 | |
| Pfizer INC. | $112.41 | 2019-2022 | |
| Novo Nordisk INC | $109.90 | 2019-2021 | |
| Lilly USA, LLC | $95.91 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $78.56 | 2019-2021 | |
| Astellas Pharma US INC | $75.16 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.60 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $57.65 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $51.45 | 2019-2021 | |
| Sanofi Pasteur INC. | $43.45 | 2019 | |
| Amarin Pharma, INC. | $41.19 | 2019-2020 | |
| Abbott Laboratories | $36.16 | 2021-2023 | Proclaim |
| Abbvie INC. | $32.67 | 2021 | |
| Vanda Pharmaceuticals INC. | $20.42 | 2020 | |
| Genentech USA, INC. | $19.42 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.08 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.83 | 2021 | |
| Amgen INC. | $16.67 | 2019 | |
| Medtronic USA, INC. | $15.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.